Rickenbach Josef Von Acquires 15,950 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Posted by Brenda Bartman on May 28th, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) Director Rickenbach Josef Von bought 15,950 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were bought at an average price of $1.05 per share, for a total transaction of $16,747.50. Following the completion of the transaction, the director directly owned 34,824 shares in the company, valued at approximately $36,565.20. This represents a 84.51% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Rein Therapeutics Price Performance

Shares of NASDAQ RNTX traded up $0.05 during trading on Thursday, hitting $1.11. 425,172 shares of the company were exchanged, compared to its average volume of 1,491,003. The company has a market cap of $94.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.42. Rein Therapeutics Inc. has a 1 year low of $0.95 and a 1 year high of $2.18. The firm’s fifty day moving average price is $1.33 and its 200 day moving average price is $1.31.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.30. On average, research analysts forecast that Rein Therapeutics Inc. will post -1.63 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new position in Rein Therapeutics in the 3rd quarter valued at about $35,000. HRT Financial LP acquired a new position in Rein Therapeutics in the 4th quarter valued at about $38,000. Chicago Partners Investment Group LLC raised its stake in Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Rein Therapeutics in the 2nd quarter valued at about $68,000. Finally, Jane Street Group LLC acquired a new position in Rein Therapeutics in the 4th quarter valued at about $72,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Rein Therapeutics to a “sell” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Get Our Latest Stock Report on Rein Therapeutics

Rein Therapeutics Company Profile

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.